Sequana Medical

Sequana Medical is a pioneer in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure. The company is commercially active with their in medical devices (incl patented & wireless alfapump® implant, and DSR® platform) to remove excess fluid, providing significant clinical benefits for patients on the one hand, and lowering costs for healthcare systems on the other.

Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and is headquartered in Ghent, Belgium.

PMV was involved with Sequana for the first time at the end of 2018 in the role of strong cornerstone investor in the Euronext-Brussels IPO (2019) raising €27.5m. PMV also played its local cornerstone investor role in follow-on investments between 2020 and 2022. The current cash runway runs until Q3 2023 and enables the company to achieve key clinical milestones in its North American liver and global heart failure programmes.